Literature DB >> 22549499

High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.

Natella Y Rakhmanina1, Michael N Neely, Edmund V Capparelli.   

Abstract

We describe an unintentional significant overdose of darunavir in a treatment-experienced adolescent with decreased darunavir susceptibility and prior treatment failure on darunavir therapy. Minimal toxicity and improved virologic suppression observed with an overdose have prompted consideration of the continued use of a higher than recommended dose. Pharmacokinetic and pharmacodynamic evaluations justified the individualized use of high-dose darunavir, which resulted in virologic suppression, improved CD4 cell count, and resolution of toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549499      PMCID: PMC3354040          DOI: 10.1097/FTD.0b013e3182511efe

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

Review 1.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

2.  Developmental pharmacology in adolescence. The inauguration of a new field.

Authors:  K Hein
Journal:  J Adolesc Health Care       Date:  1987-01

3.  The effect of age, gender, and sexual maturation on the caffeine breath test.

Authors:  G H Lambert; D A Schoeller; A N Kotake; C Flores; D Hay
Journal:  Dev Pharmacol Ther       Date:  1986

4.  Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Vanitha Sekar; Brian Woodfall; Goedele De Smedt; Eric Lefebvre; Monika Peeters; Richard M Hoetelmans
Journal:  Antivir Ther       Date:  2007

5.  Pubertal changes in net renal tubular secretion of digoxin.

Authors:  L A Linday; D E Drayer; M A Khan; C Cicalese; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1984-04       Impact factor: 6.875

6.  Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

Authors:  Isabelle Pellegrin; Linda Wittkop; Laurence Morand Joubert; Didier Neau; Diane Bollens; Mojgan Bonarek; Pierre-Marie Girard; Hervé Fleury; Bart Winters; Marie-Claude Saux; Jean-Luc Pellegrin; Rodolphe Thiébaut; Dominique Breilh
Journal:  Antivir Ther       Date:  2008

Review 7.  Personalized therapeutics: HIV treatment in adolescents.

Authors:  N Y Rakhmanina; E V Capparelli; J N van den Anker
Journal:  Clin Pharmacol Ther       Date:  2008-10-01       Impact factor: 6.875

8.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

9.  Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

Authors:  Stéphane Blanche; Rosa Bologna; Pedro Cahn; Sorin Rugina; Patricia Flynn; Claudia Fortuny; Peter Vis; Vanitha Sekar; Ben van Baelen; Inge Dierynck; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

10.  Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

  10 in total
  4 in total

Review 1.  Pharmacotherapy of pediatric HIV infection.

Authors:  Natella Rakhmanina; B Ryan Phelps
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

Review 2.  A review of the toxicity of HIV medications.

Authors:  Asa M Margolis; Harry Heverling; Paul A Pham; Andrew Stolbach
Journal:  J Med Toxicol       Date:  2014-03

3.  Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.

Authors:  James M Mikula; Chiu-Bin Hsiao; Joshua R Sawyer; Qing Ma; Gene D Morse
Journal:  AIDS Res Treat       Date:  2013-07-17

Review 4.  Darunavir: A Review in Pediatric HIV-1 Infection.

Authors:  Gillian M Keating
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.930

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.